State of New Jersey Common Pension Fund D Sells 242 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of New Jersey Common Pension Fund D reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,698 shares of the biotechnology company’s stock after selling 242 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Sarepta Therapeutics were worth $4,084,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of SRPT. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. EP Wealth Advisors LLC raised its holdings in Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after buying an additional 120 shares during the period. Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares during the last quarter. Finally, Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $114.32 on Wednesday. The company has a quick ratio of 3.19, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50 day moving average price of $125.15 and a 200-day moving average price of $132.80. Sarepta Therapeutics, Inc. has a 52 week low of $76.61 and a 52 week high of $173.25. The firm has a market capitalization of $10.92 billion, a PE ratio of 91.46 and a beta of 0.81.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. StockNews.com raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Evercore ISI lowered their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $181.33.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.